Abstract
Tumor necrosis factor (TNF) blockers are promising therapeutic agents for patients with conventional therapy insensitive inflammatory diseases. Unfortunately, their use has been associated with an increased rate of malignancies, leukemia, psoriasis and other immune diseases. The U. S. Food and Drug Administration (FDA) is requiring stronger warnings in the prescribing information for TNF blockers. Healthcare Professionals should pay close attention to severe adverse effects of TNF blockers and drug safety.
| Original language | English (US) |
|---|---|
| Journal | Chinese Pharmacological Bulletin |
| Volume | 25 |
| Issue number | 9 |
| State | Published - Jan 1 2009 |
| Externally published | Yes |
Fingerprint
Keywords
- Adalimumab
- Adverse effect
- Etanercept
- Infliximab
- Rational administration
- Tumor necrosis factor blocker
ASJC Scopus subject areas
- Pharmacology
Cite this
Pay close attention to severe adverse effects of tumor necrosis factor blockers. / Wang, Qingtong; Wei, Wei.
In: Chinese Pharmacological Bulletin, Vol. 25, No. 9, 01.01.2009.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pay close attention to severe adverse effects of tumor necrosis factor blockers
AU - Wang, Qingtong
AU - Wei, Wei
PY - 2009/1/1
Y1 - 2009/1/1
N2 - Tumor necrosis factor (TNF) blockers are promising therapeutic agents for patients with conventional therapy insensitive inflammatory diseases. Unfortunately, their use has been associated with an increased rate of malignancies, leukemia, psoriasis and other immune diseases. The U. S. Food and Drug Administration (FDA) is requiring stronger warnings in the prescribing information for TNF blockers. Healthcare Professionals should pay close attention to severe adverse effects of TNF blockers and drug safety.
AB - Tumor necrosis factor (TNF) blockers are promising therapeutic agents for patients with conventional therapy insensitive inflammatory diseases. Unfortunately, their use has been associated with an increased rate of malignancies, leukemia, psoriasis and other immune diseases. The U. S. Food and Drug Administration (FDA) is requiring stronger warnings in the prescribing information for TNF blockers. Healthcare Professionals should pay close attention to severe adverse effects of TNF blockers and drug safety.
KW - Adalimumab
KW - Adverse effect
KW - Etanercept
KW - Infliximab
KW - Rational administration
KW - Tumor necrosis factor blocker
UR - http://www.scopus.com/inward/record.url?scp=72149087945&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=72149087945&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:72149087945
VL - 25
JO - Chinese Pharmacological Bulletin
JF - Chinese Pharmacological Bulletin
SN - 1001-1978
IS - 9
ER -